{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-006178","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.942634+00:00","generated_at":"2026-06-19T16:06:19.322101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant Q3 net loss widens to $385M; VTAMA revenue $9.2M, RVT-3101 Phase 2b positive","bullets":["Net loss of $384.9M ($0.49 per share) for Q3 FY2023, compared to net loss of $306.1M ($0.41) a year ago.","VTAMA net product revenue $9.2M; nearly 100,000 prescriptions written by ~8,600 prescribers since launch; 57% of commercial lives covered.","RVT-3101 Phase 2b TUSCANY-2: 31% clinical remission (p=0.01) and 40% endoscopic improvement (p=0.01) at expected Phase 3 dose; biomarker-positive patients achieved 40%/56% rates.","Completed $230M upsized equity offering; pro forma cash $1.9B, extending runway into 2H 2025.","Topline data expected from ADORING 1 (VTAMA in atopic dermatitis) in March 2023 and ADORING 2 in May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-006178","json":"https://secwatch.observer/filing/0001140361-23-006178.json","markdown":"https://secwatch.observer/filing/0001140361-23-006178.md","text":"https://secwatch.observer/filing/0001140361-23-006178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/brhc10048029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:06:19.322101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e000663eb004883200e639737614ffd5fa904b79","claim":"Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2022.","evidence_excerpt":"On February 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}